CVI-CT-001 / CHA Vaccine Institute - LARVOL DELTA

CHA Vaccine Institute's TLR-targeting drug CVI-CT-001 uses AI to reveal cancer-killing mechanism (Korea Biomedical Review) - "The study analyzed transcriptome data from cell lines treated with CVI-CT-001, revealing that the drug activates TLR signaling pathways, particularly in prostate and colon cancer cells....This activation leads to oxidative phosphorylation (OXPHOS) and the production of reactive oxygen species (ROS) via the PI3K-AKT and JAK-STAT pathways, selectively inducing cancer cell death....The study also identified specific gene clusters associated with this process, suggesting that CVI-CT-001’s effectiveness may stem from its ability to enhance the sensitivity of prostate cancer cells to treatment."

Preclinical